All In Biotech

Drug Trial Radar · NCT03155061

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase 1 Dose Escalating and Expansion Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

183

Planned (sponsor's estimate)

Start

Apr 19, 2017

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
May 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • ONO-4578Drug

    ONO-4578 specified dose on specified days

  • ONO-4538Drug

    ONO-4538 specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the safety (adverse event, clinical laboratory test, 12-lead electrocardiography, chest X-ray, ECOG performance status)Time frame: Through study completion, an average of 1 year

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Aichi Clinical Site 1

    Nagoya, Aichi-ken, Japan

  • Aichi Clinical Site 2

    Toyoake, Aichi-ken, Japan

  • Chiba Clinical Site 1

    Kashiwa, Chiba, Japan

  • Ehime Clinical Site1

    Matsuyama, Ehime, Japan

  • Fukuoka Clinical Site 1

    Fukuoka, Fukuoka, Japan

  • Fukuoka Clinical Site 2

    Fukuoka, Fukuoka, Japan

  • Gunma Clinical Site 1

    Ōta, Gunma, Japan

  • Hokkaido Clinical Site 1

    Sapporo, Hokkaido, Japan

  • Iwate Clinical Site 1

    Yahaba-cho, Iwate, Japan

  • Kanagawa Clinical Site 2

    Sagamihara, Kanagawa, Japan

  • Kanagawa Clinical Site 1

    Yokohama, Kanagawa, Japan

  • Osaka Clinical Site 2

    Hirakata, Osaka, Japan

  • Osaka Clinical Site 1

    Osaka, Osaka, Japan

  • Osaka Clinical Site 3

    Sakai, Osaka, Japan

  • Osaka Clinical Site 4

    Takatsuki, Osaka, Japan

  • Saitama Clinical Site 2

    Hidaka, Saitama, Japan

  • Saitama Clinical Site 1

    Ina-machi, Saitama, Japan

  • Shizuoka Clinical Site 1

    Nagaizumi-Cho, Shizuoka, Japan

  • Tokyo Clinical Site 1

    Chuo-ku, Tokyo, Japan

  • Tokyo Clinical Site 2

    Koto-ku, Tokyo, Japan

  • Tokyo Clinical Site 3

    Shinjyuku-ku, Tokyo, Japan

  • Tokyo Clinical Site 4

    tabashi City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.